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Single-unit extracellular recording was carried out in rats to characterize the effects of dynorphin and several 
structurally related peptides on hippocampal pyramidal cell activity. Dynorphin, applied electrophoretically or by 
pneumatic pressure, produced a dose-dependent depression of both spontaneous and glutamate-evoked discharge in a 
majority (63%) of CA 1 and CA 3 cells tested. In addition, a small number of cells in both cellular fields responded to 
the peptide with a prolonged elevation in firing. The inhibitory effects of dynorphin were not blocked by naloxone. 
Moreover, administration of des-tyrosine-dynorphin depressed the firing of pyramidal cells in a manner similar to that 
of the parent compound. Ethylketocyclazocine produced a mixed pattern of excitatory and inhibitory effects, whereas 
naloxone-sensitive elevations in firing were most often observed with the application of dynorphin-(1-8). Application 
of [LeuS]enkephalin produced only facilitations in pyramidal cell firing. The possibility is raised that biologically 
significant non-opiate actions, in addition to potent opiate-mediated effects, may occur upon release of pro-dynorphin 
peptides in the hippocampus. 




In vitro pharmacological  studies strongly sug- 
gest that dynorphin  interacts with x opioid binding 
sites (Chavkin et al., 1982, Corbet t  et al., 1982; 
James et al., 1984). Thus, dynorphin  resembles 
ethylketocyclazocine and other putative opiate 
agonists in a number  of  in vitro bioassays utilizing 
smooth muscle (Huidobro-Toro  et al., 1981; 
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Chavkin et al., 1982; Yoshimura et al., 1982). 
Moreover,  the binding of  [3H]dynorphin to brain 
neural membranes  is not  readily displaced by 
opiates such as d ihydromorphine  or [D-Ala2,D - 
leuS]enkephalin, but  is easily displaced by x opioid 
agonists (Young et al., 1983). Paradoxically, dy- 
norphin  is equipotent  in displacing tritiated ~ and 
compounds  from rat neural membranes  (Young 
et al., 1983). Nevertheless, it is quite clear from the 
ability of naloxone to completely block all of these 
effects that dynorphin  has definite opiate actions 
that resemble those of  the opiates. 
The in vivo pharmacology of  dynorphin  largely 
encompasses the predicted set of  x opioid effects, 
but  is suggestive of a wide range of non-opiate  
effects as well. Thus, a number  of the effects of 
dynorphin  observed in rats and mice are com- 
pletely unaffected by extremely high doses of  
naloxone. Most prominent  among these are its 
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effect on motor activity and grooming behavior 
(Herman et al., 1980; Walker et al., 1981), changes 
in the electroencephalogram (Walker et al., 1982a), 
and its depressant effects on hippocampal unit 
firing (Walker et al., 1982a). The non-opioid na- 
ture of these effects is further documented by the 
finding that at least this subset of dynorphin ef- 
fects is equally well produced by des-Tyr-dy- 
norphin, a fragment devoid of potency in displac- 
ing/,t, 8 or ~¢ opiates from their binding sites in the 
central nervous system (CNS) (Walker et al., 
1982a). Other effects of dynorphin, such as the 
inhibition of morphine analgesia (Walker et al., 
1982b), the production of spinally mediated in- 
hibition of thermal pain (Przewlocki et al., 1983), 
the elicitation of grooming (Aloyo et al., 1982), 
and motor paralysis (Faden and Jacobs, 1984), are 
also mimicked by des-Tyr-dynorphin. Taken to- 
gether, these findings suggest that the in vivo 
pharmacology of dynorphin has two components, 
one which is opiate in nature and mediated through 
the familiar opiate receptor mechanisms and 
another which is non-opiate and mediated through 
an unknown mechanism. 
In the present study, a further evaluation was 
carried out of the effects of dynorphin on single 
neurons in the rat CNS. The experiments were 
conducted in hippocampus because dynorphin is 
present there in significant amounts (Khachaturian 
et al., 1982; McGinty et al., 1983), and because 
much insight has recently been gained into the 
effects of opioid peptides in this brain structure 
(Zieglg~nsberger et al., 1979; Dunwiddie et al., 
1980; Dingledine, 1981; Siggins and Zieglg~ns- 
berger, 1981). The primary aim was to characterize 
relationships among several related compounds 
with opiate activity: the putative ~¢ opiate agonist 
ethylketocyclazocine, dynorphin, an amino-termi- 
nal fragment of dynorphin believed to be the 
major dynorphin-like peptide released in the CNS 
(dynorphin-(1-8)) (Weber et al., 1982) and 
[Leu 5 ]enkephalin. 
2. Materials and methods 
Thirty-eight male Sprague-Dawley rats (Charles 
River), weighing 225-320 g, were used in this study. 
In the initial experiments (n = 16), animals were 
anesthetized with chloral hydrate, 400 mg/kg  i.p., 
with additional injections of approximately 80 
mg/kg  being given as needed. In the remaining 
experiments (n = 22), anesthesia was induced with 
halothane (2.5% in air), the animal intubated and 
then maintained at 0.5-0.75% halothane for the 
rest of the experiment. After the animal was fixed 
in a stereotaxic apparatus, a craniotomy was per- 
formed over the frontoparietal cortex, extending 
from 2.5 to 4.0 mm posterior to bregma and 1.0 to 
4.0 mm lateral from the midline. The dura was 
excised and the exposed cortical surface covered 
with 2% agar in balanced salt solution to prevent 
drying. Body temperature was maintained con- 
stant at 37°C by means of a servo-feedback cir- 
cuit. 
Five-barreled glass micropipettes (3-6 tzm diam- 
eter tips), constructed according to the procedures 
of Palmer et al. (1980), were used to record ex- 
tracellularly from single hippocampal pyramidal 
cells and to apply drugs in the immediate vicinity 
of the neuron being recorded. The center barrel, 
filled with 4 M NaC1 or a solution of 2 M NaC1 
saturated with fast green dye, was used for record- 
ing. Three side barrels were backfilled with various 
combinations of the following solutions: dy- 
norphin (dynorphin-(1-17)) 4 mM; dynorphin-(1-8) 
8 mM (Peninsula Laboratories, Inc.); des-Tyr-dy- 
norphin (dynorphin-(2-17)) 5-10 mM; [LeuS]en - 
kephalin 25 mM (Peninsula Laboratories, Inc.): 
ethylketocyclazocine 10 mM, pH 4 (Sterling- 
Winthrop); naloxone hydrochloride 50 mM, pH 4 
(Endo Laboratories); L-glutamate 250 raM, pH 8 
(Sigma), bicuculline 50 mM, pH 5 (Sigma) and 
MgCI 2 100 mM, pH 6 (Sigma). Dynorphin and 
des-Tyr-dynorphin were synthesized by solid phase 
methods by Dr. D.H. Coy (Tulane University) and 
provided generously as a gift. All peptides were 
dissolved in 0.9% NaC1 (pH 6.5-7.0) and ejected 
from the barrels either by application of pneu- 
matic pressure (1-25 psi range, 5-15 s) or with 
cationic current by electroosmosis. In some in- 
stances, peptides were ejected from the same bar- 
rel using both methods. The remaining drugs were 
ejected microiontophoretically as cations, except 
for glutamate which was ejected as an anion, or 
retained in the barrels by application of 15 nA 
holding currents of opposite polarity. Automatic 
current balancing was maintained through a fourth 
peripheral barrel containing 3 M NaCI. Positive 
and negative currents were independently passed 
through this barrel to check for possible current 
artifacts. In both the pressure ejection and electro- 
phoretic experiments, all responses to given doses 
of drugs had to share reproducibility and reversi- 
bility over several trials to be considered valid. 
Control ejections were used to test for pH effects 
of the drug solutions as well as for pressure ejec- 
tion artifacts. In some experiments, glutamate was 
intentionally leaked from one peripheral barrel in 
order to increase the firing rate of slowing dis- 
charging units and to activate normally quiescent 
cells. 
Extracellular action potentials were recorded 
from single hippocampal pyramidal neurons within 
the CA 1 and CA 3 cellular fields. To facilitate 
accurate localization of the recording pipette to 
either CA 1 or CA3, field potential analysis was 
often performed with the aid of a bipolar stimulat- 
ing electrode placed ipsilaterally in the dentate 
hilus. Both stimulation and recording locations 
were within the same coronal plane, with the 
stimulating electrode maintained at a position of 
1.2 mm medial to the midline. Hippocampal  neu- 
rons were most frequently encountered in the re- 
gion where the maximum amplitude of the evoked 
population spike response was observed. 
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Action potentials of pyramidal neurons, identi- 
fied by their depth from the cortical surface and 
typical bursting pattern, were monitored on an 
oscilloscope, separated from background activity 
and converted to uniform voltage pulses by a 
window discriminator. These pulses were in- 
tegrated over intervals of 1 or 2 s by an electronic 
ratemeter and the average firing rate of the cells 
displayed on a strip chart recorder to monitor 
drug effects. Constancy of spike amplitude was 
also monitored throughout the course of each ex- 
periment to control for local anesthetic effects of 
the drugs being tested. Upon termination of an 
experiment, the position of the recording site was 
marked by passing an anionic current of 20-30 ~A 
for 10 min through the recording barrel, thus 
depositing a spot of fast green dye at the electrode 
tip. The location of the recording site, with respect 
to the CA 1 and CA3 hippocampal fields, was then 
verified histologically in 50 ~m frozen sections 
stained with cresyl violet and neutral red. 
3. Results 
The effects of dynorphin and several structur- 
ally related opioid peptides were examined on 104 
hippocampal pyramidal neurons. Thirty-nine of 
these cells were recorded in rats (n = 16) anesthe- 
tized with chloral hydrate and the remainder re- 
TABLE 1 
Effects of dynorphin and structurally related peptides on hippocampal pyramidal cell activity. 
Test substance Response to peptide application 
Total cells Excitation Inhibition Biphasic No response 
CA l pyramidal  cells 
Dynorphin 37 4 24 4 5 
Des-Tyr-dynorphin 8 0 4 0 4 
Dynorphin-(1-8) 7 3 0 0 4 
[Leu 5 }enkephalin 8 5 0 1 2 
Ethylketocyclazocine 9 2 3 2 2 
CA 3 pyramidal  cells 
Dynorphin 44 6 27 4 7 
Des-Tyr-dynorphin 11 1 7 0 3 
Dynorphin-(1-8) 12 5 3 0 4 
[Leu 5 ]enkephalin 8 7 0 0 1 
Ethylketocyclazocine 10 2 3 3 2 
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corded in halothane-anesthetized animals (n = 22). 
Individual CA 1 and CA 3 pyramidal cells re- 
sponded qualitatively in the same direction to a 
particular opioid peptide under both anesthetic 
conditions. Furthermore, no clear relationships 
could be observed between the responsiveness of 
neurons to the opioids and their location within 
the CA 1 and CA 3 cellular fields. Results obtained 
at different electrode positions within the hippo- 
campus and under the differing conditions of 
anesthesia have, therefore, been grouped together. 
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Fig. 1. (AI) Continuous ratemeter record shows dose-dependent inhibitory effect of dynorphin (DYN) on the spontaneous activity of 
a CA 1 pyramidal cell. Note that application of DYN (dashed line) by pneumatic (upper record) and electrophoretic ejection (lower 
record) produced similar inhibitory effects. Iontophoresis of naloxone (solid line) failed to block or reverse inhibitions produced by 
DYN. Note also that administration of naloxone at high dose levels (30 nA, lower record) produced a direct slowing of pyramidal cell 
activity. (A2) Oscilloscope record shows the effects of electrophoretic application of DYN on the discharge frequency and spike 
amplitude of the pyramidal cell shown in (1). Application of DYN (dashed line) 25 nA produced a clear reduction in the firing rate, 
accompanied by only a slight decrease in the size of the extracellularly recorded action potentials. (B) Results from an experiment on 
another CA l pyramidal cell show little effect of magnesium iontophoresis (thin line) 20 nA on inhibitions in firing produced by 
electrophoretic applications of DYN (dashed line) 35 nA. In this and all subsequent figures, bars above ratemeter records indicate 
time and duration of drug application. Numbers above bars correspond to the ejection dose level, with electrophoretic or pneumatic 
delivery being indicated in nanoamperes (nA) or pounds per square inch (psi), respectively, at initial application of a particular agent. 
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norphin, dynorphin-like peptides, [Leuh]enkepha - 
lin and ethylketocyclazocine in the 104 hippo- 
campal pyramidal neurons examined. 
3.1. Characterization of responses to dynorphin 
Dynorphin had a predominantly inhibitory ef- 
fect on the activity of hippocampal pyramidal 
cells. Application of the peptide for periods of 10 
to 30 s produced a dose-dependent depression of 
both spontaneous and glutamate-evoked discharge 
in 24 of 37 and 27 of 44 pyramidal neurons tested 
in CA] and CA 3, respectively (table 1). Only four 
CA~ pyramidal cells and six C A  3 cells displayed 
excitatory responses to dynorphin (table 1). Four 
additional pyramidal cells in each of the cellular 
fields responded in a biphasic manner to dy- 
norphin application (table 1). In these latter cases, 
both electrophoretic (n = 5) and pneumatic pres- 
sure ejections (n = 3) of the peptide resulted in an 
initial brief excitation of several seconds duration 
followed by a prolonged period of spike suppres- 
sion. 
Fig. 1 illustrates the typical pattern of inhibi- 
tory effects of dynorphin that was encountered in 
a majority of the CA] and CA 3 pyramidal neurons 
tested. As shown in this CA] cell, application of 
dynorphin by electrophoretic or pressure ejection 
produced reversible depressions in spike discharge 
which graded in magnitude and duration with the 
drug application parameters. Such depressant ef- 
fects, observed in both CA] and C A 3 ,  w e r e  typi- 
cally rapid in onset, showed little evidence of 
tachyphylaxis and were produced equally well by 
electrophoretic or pressure ejection of the peptide. 
In most cases, recovery from the inhibitory effects 
of dynorphin on cell firing occurred gradually, 
beginning within a few seconds following cessation 
of peptide application. At the higher range of 
application doses, however, neuronal activity re- 
mained depressed for a number of seconds (20-100 
s) after termination of peptide ejection, and re- 
covery was often associated with rebound in- 
creases in baseline firing (fig. 1A]). It should be 
noted that decreases in spike amplitude were ob- 
served in a small number of the cells (CA] n = 4; 
C A  3 n = 5) which showed depressant responses to 
dynorphin. The changes in spike morphology ob- 
N a l o x o n e  25nA 
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DYN.8PSi - -  .12." ..12.. 
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3 0  sec 
Fig. 2. Continuous ratemeter record shows excitations of a single CA 3 pyramidal cell produced by glutamate (GLUT) iontophoresis 
and by pressure ejection of dynorphin (DYN). Excitatory responses produced by DYN application (dashed lines) were characterized 
by slow onset and prolonged duration, whereas increases in firing produced by iontophoresis of glutamate (thick bars) showed a rapid 
onset and termination corresponding to the period of amino acid application. Note that the excitatory effects of DYN could be 
blocked (upper record) or reversed (lower record) by iontophoresis of naloxone 25 nA (thin lines) at a dose level which had no effect 
on glutamate-evoked increases in firing. 
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served in these cases were, nevertheless, associated 
with clear reductions in neuronal discharge 
frequency (fig. 1A2). In comparison, in those cells 
which showed biphasic responses to dynorphin, 
the inhibitory phase appeared to be due more to a 
decrease in action potential amplitude than to a 
decrease in the rate of neuronal firing per se. 
Excitatory responses to dynorphin, which were 
observed in 10 of the 81 pyramidal neurons ex- 
amined, appeared similar to those reported for 
other opioid peptides (Nicoll et al., 1977; Dunwid- 
die et al., 1980; French and Siggins, 1980; Henrik- 
sen et al., 1982). These excitatory effects were 
relatively slow in onset (fig. 2), beginning from 5 
to 20 s after the initiation of either electrophoretic 
or pressure ejection of the peptide. The elevations 
in firing evoked by dynorphin were notably robust 
in nature, and such effects typically extended 10 or 
more seconds beyond the period of peptide appli- 
cation (fig. 2). In five of the ten cases, application 
of dynorphin also recruited firing of previously 
quiescent neighboring units, resulting in the con- 
comitant appearance of multi-unit activity in the 
oscilloscope traces. No tachyphylaxis was ob- 
served to the excitatory action of dynorphin in any 
of the neurons, even under conditions when the 
peptide was applied repeatedly to the same cell for 
periods approaching 1 h. Antagonism of excitatory 
responses to dynorphin was achieved with 
iontophoresis of naloxone in three of four CA~ 
and four of five CA 3 pyramidal cells tested (fig. 2). 
This antagonism was unlikely to reflect a local 
anesthetic action of the opiate antagonist, since 
excitatory responses were reduced with doses of 
naloxone that had little effect on excitations evoked 
by glutamate (fig. 2). 
3.2. Nature of dynorphin's inhibitory action 
Previous studies have demonstrated predomi- 
nantly facilitating effects of opiates and opioid 
peptides on hippocampal pyramidal cell activity, 
mediated presumably through a disinhibitory 
mechanism (Zieglg~nsberger et al., 1979; Dunwid- 
die et al., 1980; Nicoll et al., 1980; Siggins and 
Zieglggnsberger, 1981). Although inhibitory re- 
sponses to these substances have also been ob- 
served in some hippocampal neurons, such de- 
pressant effects were generally considered to be 
non-specific in nature or to otherwise reflect ac- 
tions of the opioids on subpopulations of opiate 
receptors a n d / o r  hippocampal cells distinct from 
those mediating excitatory events (Nicoll et al., 
1977; Fry et al., 1979; French and Siggins, 1980). 
Bearing this in mind, several types of experiments 
were conducted to clarify the events underlying 
the inhibitory effects of dynorphin on pyramidal 
cell discharge. 
To determine whether the inhibitory responses 
to dynorphin involved the activation of opiate 
receptors, the specific opiate antagonist naloxone 
was applied prior to and concurrent with applica- 
tion of the peptide in tests on 14 pyramidal cells. 
Iontophoresis of naloxone (20 to 50 nA, 2 to 5 
min) failed in all cases either to prevent (eight of 
eight cells) or reverse (nine of nine cells) the 
inhibitory effects of dynorphin in CA~ and CA t 
(fig. 1A~). In fact, depressant responses to the 
peptide were increased in five neurons during 
administration of the opiate antagonist. In four of 
these same cells, iontophoretic administration of 
naloxone alone depressed neuronal activity di- 
rectly when ejected at current levels in excess of 30 
nA (fig. 1A 1). This depression appeared to be due 
in large part to a local anesthetic action of nalo- 
xone and was likely to account for the apparent 
increase in inhibitory potency of dynorphin ob- 
served in the presence of the antagonist. 
3.3. Lffects of structurally related opioids 
The involvement of opiate receptors in mediat- 
ing the inhibitory effects of dynorphin was further 
assessed by characterizing the actions of other 
dynorphin peptides and of ethylketocyclazocine, a 
~-receptor agonist, on hippocampal pyramidal cell 
activity. Des-Tyr-dynorphin, an opiate inactive 
fragment of dynorphin which has virtually no 
opiate binding potential (De Wied et al., 1978; 
Walker et al., 1982a), was tested on 19 neurons 
and found to have effects similar to that of the 
parent peptide (table 1). Pneumatic application of 
des-Tyr-dynorphin for periods of 10 to 20 s pro- 
duced depressions of both spontaneous and 
glutamate-evoked firing in four of eight neurons 
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Fig. 3. Comparison of the effects of dynorphin (DYN), des-Tyr-dynorphin (dT-D) and [LeuS]enkephalin (L-ENK) on the activity of a 
single CA 3 pyramidal neuron. Continuous ratemeter record illustrates dose-dependent inhibition of pyramidal cell spontaneous firing 
produced both by electrophoretic application of DYN (dashed bar) and by pressure ejection of its opiate inactive fragment dT-D (thin 
bar). Note that the inhibition produced by the two peptides displayed a similar onset and duration of effect. In comparison, 
iontophoretic application of L-ENK (thick bar) to the same neuron produced elevations in firing of slow onset and prolonged 
duration. 
similar inhibitory action was observed in three 
additional CA 3 neurons during electrophoretic ap- 
plication of the peptide. In contrast, electro- 
phoretic (n = 3) or pressure ejection (n = 16) of 
des-Tyr-dynorphin elicited excitation of neuronal 
firing in only a single CA 3 pyramidal cell (table 
1). Seven cells displayed decreases in spike ampli- 
tude during pneumatic ejection of the peptide and 
were excluded from the analysis because of the 
possibility of pressure artifacts. 
The actions of des-Tyr-dynorphin on pyramidal 
cell activity appeared to closely mimic those of 
dynorphin both in kind and quality of the effect. 
This similarity of action was demonstrated in tests 
on 14 neurons in which the effects of the two 
peptides were compared directly on the same neu- 
ron. Fig. 3 shows the results of a typical experi- 
ment on a single CA 3 pyramidal cell. As shown in 
this neuron, application of either dynorphin or 
des-Tyr-dynorphin produced rapid and readily re- 
versible depressions of spontaneous firing which 
graded in magnitude and duration with the level of 
electrophoretic current or pneumatic pressure used 
to eject a particular peptide. Iontophoresis of 
[LeuS]enkephalin, in comparison, produced an 
elevation in cell discharge which was characterized 
by a slow onset and prolonged duration. Overall, 
eight of the 14 cells (four each in CA] and CA3) 
were inhibited by administration of dynorphin, 
and in seven of these des-Tyr-dynorphin had simi- 
lar depressant effects (table 2). Two additional 
cells in CA 3 responded to dynorphin with exci- 
tation and in one of these cells des-Tyr-dynorphin 
elicited an identical response (table 2). 
The actions in hippocampus of dynorphin-(1-8), 
an amino-terminal fragment which appears to be 
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TABLE 2 
Direct comparisons of the effects of dynorphin and related 
peptide fragments on pyramidal cell discharge. Values in tables 
indicate the number of cells responding in the same manner to 
dynorphin and a particular fragment peptide. Comparisons 
with des-Tyr-dynorphin were made in 6 CA 1 and 8 CA 3 cells: 
in 8 CA 3 cells with dynorphin-(1-8); and 6 CA 1 and 5 CA 3 
cells with [LeuS]enkephalin. 
Effects of dynorphin (No. of cells) 
Inhibition Excitation No effect 
Effects of peptide fragments 
des-Tyr-Dynorphin 
Inhibition 7 - 
Excitation - 1 - 
No effect 1 1 4 
Dynorphin-(1-8) 
Inhibition 2 
Excitation 2 1 - 
No effect 2 - 1 
[Leu 5 ]enkephalin 
Inhibition 
Excitation 7 - 1 
No effect 1 - 2 
the predominant  dynorphin-l ike peptide in brain 
(Weber et al., 1982) were examined in seven CA 1 
and twelve CA 3 pyramidal  cells. Applicat ion of 
dynorphin-(1-8) had a predominant ly  excitatory 
effect in CA 3, increasing the discharge rate of five 
neurons, while depressing activity in three cells 
(table 1). Three pyramidal  cells in CA1 also re- 
sponded to dynorphin-(1-8) in an excitatory 
manner  (table 1). These excitatory effects were 
observed with both  pressure (three cells) and elec- 
t rophoretic ejection (five cells) of the peptide and 
were characteristically of slow onset and pro- 
longed durat ion (fig. 4A). In three of four cells 
tested, excitatory responses to dynorphin-(1-8) 
were blocked by administrat ion of naloxone at 
iontophoret ic  doses which caused little or no de- 
pression in spontaneous firing (fig. 4A). The in- 
hibitory effects of  dynorphin-(1-8) which were 
produced in three cells by pressure ejection of the 
octapept ide were not antagonized by naloxone 
(fig. 4B). The remaining eight cells in which dy- 
norphin-(1-8) was tested showed no response to 
either electrophoretic or pressure application of 
the octapeptide (table 1). 
Differences in the effects of dynorphin and 
dynorphin-(1-8) on hippocampal  unit activity were 
assessed directly by comparing the actions of the 
two peptides on the same cell. Testing of both 
peptides was done on eight CA~ neurons with the 
method of their delivery being parti t ioned equally 
between pressure and electrophoretic application. 
Dynorphin  showed a marked inhibitory potency, 
depressing spontaneous firing in six of the neurons 
(table 2). Two of these units were also inhibited by 
dynorphin-(1-8);  however administration of the 
octapeptide caused marked elevations in firing in 
two other cells f rom this same population. Both 
peptides produced an elevation in firing in another 
neuron. Nonetheless, the response of this cell to 
dynorphin  appeared atypical in that an initial 
excitatory effect of the peptide was converted to a 
depressant action upon repeated dynorphin ad- 
ministration (fig. 4A). Dynorphin-( l -8)  had no 
effect on three of the eight neurons tested, suggest- 
ing a lower potency relative to dynorphin,  similar 
to that observed in cumulative trials involving 
different populat ions of hippocampal  pyramidal 
cells (table 1). 
Shortening of the dynorphin  molecule at its 
carboxy terminus has been shown both in receptor 
binding studies and in smooth muscle bioassays to 
result in a progressive decrease in the potency and 
~-receptor selectivity of the respective fragment 
peptide (Chavkin and Goldstein, 1981; Corbett  et 
al., 1982; James et al., 1984). To evaluate the 
possibility that the observed differences in actions 
of dynorphin  and dynorphin-(1-8) might reflect 
such a difference in their ~¢ selectivity, the effects 
of ethylketocyclazocine on pyramidal  cell activity 
were compared with those of the dynorphin 
peptides. In comparison with dynorphin ' s  pre- 
dominant  inhibitory action, ethylketocyclazocine 
produced a mixed pattern of excitatory and inhibi- 
tory effects. Three of the nine and ten cells ex- 
amined in CA1 and C A >  respectively, were in- 
hibited by application of ethylketocyclazocine, 
while two cells in each of the cellular fields re- 
sponded to the ~ agonist with an elevation in firing 
(table 1). In addition, five neurons showed bi- 
phasic responses to ethylketocyclazocine which 
consisted of an initial brief inhibition followed by 
a more prolonged excitatory phase, 
In six cases, the effects of ethylketocyclazocine 
and dynorphin-(1-8) were compared directly on 
the same cell. Both agents produced a dose-depen- 
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dent inhibition of firing in two CA 3 neurons. 
These inhibitory effects appeared similar in nature 
except for a more rapid onset observed with the 
A Naloxone 20nA 
DYN (~-8) 9 psi 9 9 9 
E . 
DYN o-8) 6PSi 
DYN 35nA 3,5 35 
5 0 s e e  
B 
EKC 3 8 n A  ..30 
Na loxone 25nA 
EKC 30nA 30 
DYN (~-8) 8P si 8 8 
50  sec 
Fig. 4. (A) Continuous ratemeter record compares the effects of dynorphin-(1-8) (DYNd_8)) with that of dynorphin (DYN) on the 
activity of a CA 3 pyramidal cell. Application of DYN(I_s) (dashed lines) by pressure ejection produced a dose-dependent elevation in 
the spontaneous cell firing. This facilitating effect of DYN(]_8) could be reversed or blocked by iontophoresis of naloxone 20 nA (thin 
line). Electrophoretic application of DYN (thick bars) onto the same neuron had a biphasic effect, producing an initial excitatory 
response which converted to inhibition upon subsequent applications of the peptide. (B) Ratemeter records show inhibition of firing of 
another CA 3 pyramidal cell produced by administration of ethylketocyclazocine (EKC) and dynorphin-(1-8) (DYNd_8)). Pneumatic 
application of DYNd_8) (dashed lines) produced a gradual depression in neuronal firing which graded in magnitude with the level of 
ejection pressure. Electrophoretic administration of EKC (thin bars) produced inhibitions of cell firing having a much more rapid 
onset than those produced by DYN(I_8). Iontophoresis of naloxone 25 nA (thin line) failed to block the inhibitory effects of either 
compound. 
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alkaloid (fig. 4B). Iontophoresis of naloxone failed 
to block the depressant actions of ethylketo- 
cyclazocine or dynorphin-(1-8) in either cell (fig. 
4B). Application of dynorphin-(1-8) or ethylketo- 
cyclazocine produced marked increases in sponta- 
neous firing in another CA 3 neuron and in one 
CA~ pyramidal cell. In addition, one cell in each 
cellular field failed to respond to dynorphin-(1-8) 
application, but showed biphasic responses to eth- 
ylketocyclazocine. 
In additional experiments, the effects of the 
dynorphin peptides on hippocampal unit activity 
were compared directly with the actions of 
[LeuS]enkephalin on the same population of cells. 
The actions of dynorphin were examined together 
with those of [LeuS]enkephalin in six CA 1 and five 
CA 3 pyramidal neurons. Four neurons in each of 
the cellular fields were inhibited by pressure (n = 4) 
or electrophoretic application (n = 4) of dynorphin 
(table 2). In seven of these cells, electrophoretic 
administration of [LeuS]enkephalin produced 
elevations in firing (fig. 3 and table 2). [LeuS]en - 
kephalin produced similar excitatory effects in two 
of three additional neurons which did not respond 
to the application of dynorphin (table 2). Whereas 
naloxone antagonized the excitatory effects of 
[LeuS]enkephalin in three of four cells tested, the 
depressant responses of these neurons to dy- 
norphin were not blocked by application of the 
antagonist. 
Direct comparison were also made between the 
effects of dynorphin-(1-8) and [Leu 5]enkephalin in 
three CA 3 pyramidal cells. Administration of 
[Leu ~ ]enkephalin resulted in increased firing in all 
three neurons. Similar facilitating effects were pro- 
duced in two of the cells during electrophoretic as 
well as pressure ejection of dynorphin-(1-8). The 
excitatory effects of dynorphin-(1-8) and [LeuS]en - 
kephalin in both cells were antagonized by 
iontophoresis of naloxone. Pressure application of 
dynorphin-(1-8) had no effect on the firing of the 
third cell tested. 
3.4. Cellular mediation of dynorphin's inhibitory ac- 
tion 
A final series of experiments was performed to 
gain insight into the cellular mechanism(s) un- 
derlying dynorphin's inhibitory effect on pyra- 
midal cell activity. The possibility that the inhibi- 
tions in cell firing produced by application of the 
peptide might reflect a direct action of dynorphin 
on pyramidal cells was tested initially by examin- 
ing neuronal responses to dynorphin under condi- 
tions in which ongoing synaptic activity was re- 
duced or eliminated by concurrent iontophoretic 
administration of magnesium (Nicoll, 1971). In 
these experiments, presynaptic activity was judged 
to be effectively abolished during magnesium ad- 
ministration by the demonstrated blockade of or- 
thodromic activation of CA 1 and CA 3 pyramidal 
cells, respectively, following electrical stimulation 
of the Schaffer collateral and mossy fiber affer- 
ents. As shown by the results from one such 
experiment (fig. 1B), electrophoretic applications 
of dynorphin consistently produced inhibitions of 
pyramidal cell firing throughout the period of 
magnesium iontophoresis. Little or no decrement 
was observed in the inhibitory effect of dynorphin 
either during or after magnesium administration in 
any of the eight pyramidal cells tested. In these 
experiments, administration of magnesium alone 
(5 to 30 nA, 2 to 7 rain) produced direct slowing of 
discharge in six of the cells and elevations in firing 
in two neurons. 
Much evidence suggests that the activity of 
hippocampal pyramidal cells is under tonic inhibi- 
tory control from local 7-aminobutyric acid 
(GABA)-containing inhibitory interneurons (An- 
dersen, 1975; Ribak et al., 1978). Because these 
interneurons have been implicated as a primary 
target of opioid action in the hippocampus (Ziegl- 
g~nsberger et al., 1979; Nicoll et al., 1980; Siggins 
and Zieglg~nsberger, 1981), experiments were next 
carried out with bicuculline to assess the possible 
involvement of GABA in the mediation of dy- 
norphin's inhibitory effects. Iontophoresis of bi- 
cuculline (20 to 65 nA, 20 to 90 s) accelerated the 
firing of all six pyramidal cells tested (data not 
shown) as would be expected assuming tonic re- 
lease of endogenous GABA. In four cells, inhibi- 
tory responses to dynorphin remained at or near 
control levels during administration of the GABA 
antagonist. In two cells, a partial antagonism of 
dynorphin responses was achieved by application 
of bicuculline several minutes prior to ejection of 
the peptide. This apparent antagonism appeared 
mainly due to a nonspecific speeding action of 
bicuculline, however, since depressions in firing 
produced by cationic current pulses were similarly 
reduced by the drug. 
4. Discussion 
The present results confirm our previously re- 
ported finding (Walker et al., 1982a) that dy- 
norphin has a predominantly depressant effect on 
hippocampal pyramidal cell activity. Fifty-one of 
the 69 CA 1 and CA 3 pyramidal cells which re- 
sponded to dynorphin showed depression in their 
firing during electrophoretic or pressure ejection of 
the peptide. These inhibitory responses graded in 
magnitude and duration directly in relation to the 
drug ejection parameters and generally occurred 
independent of any reduction in the amplitude of 
the extracellularly recorded action potentials. It 
seems unlikely, therefore, that the depressions in 
spike firing produced here by dynorphin can be 
attributed either to depolarization blockade or to a 
non-specific effect of the peptide on membrane 
excitability. The possibility that these depressant 
responses may have come from testing of the 
peptide on neurons other than pyramidal cells (see 
Zieglg~nsberger et al., 1979) can also be ruled out, 
since many of the same neurons which were in- 
hibited by dynorphin exhibited excitatory re- 
sponses to [LeuS]enkephalin in a manner similar to 
that reported by other investigators. Depressions 
in pyramidal cell firing were also produced, al- 
though to a much lesser extent, by application of 
dynorphin-(1-8), an amino-terminal fragment of 
dynorphin which appears to be the major dy- 
norphin-like peptide released in brain (Weber et 
al., 1982). Overall, we interpret these findings to 
suggest that an important component of the action 
of the dynorphin peptides in hippocampus may be 
to modulate the level of pyramidal cell activity. 
Dynorphin produced elevations in firing rate in 
a small fraction of the pyramidal cells tested. 
These excitatory effects of dynorphin appeared 
similar in character to those found with enkepha- 
lin peptides both here and in previous reports 
(Nicoll et al., 1977; Zieglg~insberger et al., 1979; 
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Dunwiddie et al., 1980; Henriksen et al., 1982). 
This spike facilitating action of dynorphin further 
resembled that of [LeuS]enkephalin in terms of its 
sensitivity to antagonism by naloxone, suggesting 
that such effects may be mediated by classical 
opioid receptors. 
Henriksen and co-workers (1983) reported a 
similar excitatory action of dynorphin on hippo- 
campal pyramidal cell discharge in rat. In contrast 
to the present findings, however, these investi- 
gators found that dynorphin had a predominantly 
facilitating effect on the firing of both CA 1 and 
CA 3 pyramidal cells. This discrepancy in experi- 
mental findings can possibly be attributed to a 
difference in the sampling methods that were used 
in the studies, and thus in the overall make-up of 
the populations of pyramidal cells on which the 
peptide was tested. Whereas all cells sampled in 
the present study either displayed significant levels 
of spontaneous activity or were driven to fire with 
glutamate, Henriksen and his coworkers confined 
their analysis of dynorphin action primarily to 
slowly firing neurons and normally quiescent cells 
(Henriksen and Chouvet, personal communi- 
cation). Conceivably, the effects of dynorphin may 
differ in these two populations of pyramidal neu- 
rons. In this regard, Hill and coworkers (1977) 
have shown that the direction of the response of 
hippocampal neurons to enkephalin peptides can 
vary with the activity level of the cell, shifting 
from excitation to depression when firing is in- 
creased by glutamate. The speculation raised here 
is that the probability of recording excitation or 
depression to dynorphin application may be re- 
lated to the excitability state of a particular neu- 
ron, which may in turn be governed by the partic- 
ular types of synaptic input the cell receives. In 
fact, our preliminary intracellular findings ob- 
tained in the hippocampal slice (Pacheco et al., 
1983) indicate that dynorphin has direct mem- 
brane actions on pyramidal neurons, and that 
these effects are voltage-dependent, changing in 
magnitude and direction in relation to the mem- 
brane potential of the cell. The results of the 
experiments with magnesium and bicuculline also 
provide evidence consistent with a postsynaptic 
mediation of dynorphin's inhibitory action on 
pyramidal cell firing. 
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Whereas the excitatory responses to dynorphm 
appear to involve the activation of classical opiate 
receptors, the nature of the events underlying the 
inhibitory effects of the peptide can not be so 
readily explained. The finding that only the facili- 
tating effects of dynorphin were effectively 
antagonized by naloxone suggests as one possibil- 
ity that different mechanisms may account for the 
excitatory and inhibitory actions observed here. 
On the other hand, the inhibitory actions of the 
peptide could reflect K opioid effects, which often 
are naloxone resistant (Gilbert and Martin, 1976; 
Hutchinson et al., 1975). This possibility is sup- 
ported by the finding that the K-receptor agonist 
ethylketocyclazocine produced depressant effects 
similar to those of dynorphin in a number of cells. 
An inhibitory effect of ethylketocyclazocine on 
pyramidal cell firing was also reported by Henrik- 
sen and coworkers (1982). In comparing the neu- 
ronal actions of opioids and opiate alkaloids hav- 
ing different receptor selectivities, these workers 
(Henriksen et al., 1983) noted further that a shift 
in agonist selectivity from /~- or 6- to K-directed 
activity was usually associated with an increase in 
the proportion of inhibitory over excitatory effects 
produced. The high incidence of excitatory effects 
found here with dynorphin-(1-8) might then be 
attributed to its greater cross reaction with /~-re- 
ceptors (Corbett et al., 1982; James et al., 1984), 
whereas, dynorphin in comparison appears to be 
predominantly K-directed (Chavkin et al., 1982; 
Corbett et al., 1982; James et al., 1984). Neverthe- 
less, the failure of naloxone to block the inhibitory 
effects of dynorphin presents considerable diffi- 
culty, since reversibility of effects by the antago- 
nist remains the sine-qua-non of opiate activity. 
Despite a marked resistance shown to naloxone 
antagonism, virtually all K opioid effects observed 
in isolated smooth muscle preparations or in brain 
homogenate binding assays can ultimately be com- 
pletely reversed by naloxone (Hutchinson et al., 
1975; Lord et al., 1977). Yet, no instance of nalo- 
xone reversal of dynorphin's depressant effect on 
pyramidal cell discharge was found here or in 
previously published reports (Henriksen et al., 
1982; Walker et al., 1982a). 
An alternative possibility to consider, based on 
the outcome of tests with naloxone, is that the 
inhibitory actions of dynorphin may be non-opiate 
in nature. Adding support to this suggestion was 
the finding that des-Tyr-dynorphin, a peptide frag- 
ment with virtually no opiate-binding potential 
(De Wied et al., 1978; Walker et al., 1982a), 
produced effects on pyramidal cell activity that 
were virtually indistinguishable from those of dy- 
norphin. It should be noted that in a variety of 
other test systems des-Tyr-dynorphin produced ef- 
fects which closely mimicked those of the full 
dynorphin sequence as well. These include effects 
in rodents on the electroencephalogram, motor 
behavior and grooming (Aloyo et al., 1982; Walker 
et al., 1982a), the inhibition of morphine-induced 
analgesia (Walker et al., 1982b), and a syndrome 
of spinal paralysis (Przewlocki et al., 1983), to 
name but a few. Thus, there seems sufficient evi- 
dence for postulating the existence of a second 
biologically active site within the dynorphin mole- 
cule which is non-opiate, but capable of potent 
physiological effects. Presumably, the profile of 
pharmacological effects produced by des-Tyr-dy- 
norphin might then reflect such a non-opiate com- 
ponent of dynorphin's action with unknown mech- 
anism. However, the recent observation that des- 
Tyr-dynorphin inhibits the amino-terminal clea- 
vage of [3H]dynorphin in brain (E.A. Young, per- 
sonal communication) raises the possibility that 
this substance may act in part by inhibiting the 
breakdown of endogenously released dynorphin. 
Experiments are presently underway to distinguish 
among these alternatives. 
In the event that dynorphin is found to have 
several active sites, it would not make the peptide 
unique. Indeed, such is the case for y-endorphin, 
whose des-tyrosine counterpart is non-opiate but 
very potent biologically (De Wied et al., 1978). 
Non-opiate binding sites for fi-endorphin have 
been documented in the periphery (Schweigerer et 
al., 1983). Moreover, it has recently been reported 
that a centrally occurring carboxy-terminal clea- 
vage of B-endorphin results in the secretion of a 
neurally active dipeptide (Smyth et al., 1983) and a 
fragment of ~-endorphin (/~-endorphin-(1-27)) 
having considerably reduced activity at opiate 
receptors (see Akil and Watson, 1983). In view of 
these findings, and given that opioid peptides 
(namely, dynorphin A, a-neo-endorphin and 
rimorphin) account for less than 20 percent of the 
total pro-dynorphin precursor, it might be fruitful 
to consider the possibility that biologically signifi- 
cant non-opiate actions, in addition to opiate-re- 
lated effects, may occur upon the liberation of 
pro-dynorphin peptides. 
A final issue concerns the extent to which the 
effects found here with the application of dy- 
norphin peptides might reflect a normal physio- 
logical action of the dynorphin input to hippo- 
campus. Radioimmunoassay and immunocyto- 
chemical studies have revealed that dynorphin-like 
immunoreactive (IR) material is present in hippo- 
campus in high concentrations within the dentate 
granule cell-mossy fiber pathway (Khachaturian et 
al., 1982; McGinty et al., 1983). Much of this 
dynorphin-IR appears to correspond to the 
amino-terminal octapeptide fragment, dynorphin- 
(1-8) (Weber et al., 1982), although appreciable 
amounts of the heptadecapeptide form of dy- 
norphin have also been detected and shown re- 
cently to be released (Chavkin et al., 1983). Classi- 
cally, the mossy fibers have been thought to mono- 
synaptically excite the C A 3 - C A  4 pyramidal neu- 
rons, presumably through the release of a conven- 
tional amino acid neurotransmitter (Cotman, 
1981). Yet, the finding in this study that dy- 
norphin-(1-8) exerted potent facilitating effects on 
pyramidal cell activity suggests that a dynorphin- 
like peptide may figure prominently in mediating 
the action of this intrinsic hippocampal fiber sys- 
tem. A similar argument could be made for dy- 
norphin, itself, since excitatory effects were also 
produced by the complete peptide sequence in 
some neurons. Nevertheless, it could be that dy- 
norphin peptides coexist with an excitatory amino 
acid transmitter within the same mossy fiber 
terminals, and that the actions of the peptides are 
normally co-expressed with that of the classical 
neurotransmitter. Indeed, this suggestion is in 
keeping with recent immunohistochemical data 
which demonstrate such coexistence of neuro- 
peptides and classical transmitters in a variety of 
different neurons (Lundberg and H6kfelt, 1983). 
In a number of these cases the peptides appear to 
modify the effects caused by the classical agent. 
Conceivably, the inhibitory responses observed 
here with dynorphin could reflect a similar peptide 
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action, which may function normally to modulate 
the effectiveness of synaptic transmission at mossy 
fiber-pyramidal cell junctions. Insight into these 
questions requires that in future studies one con- 
sider the actions of dynorphin peptides within the 
context of a dynamic interplay with ongoing hip- 
pocampal synaptic circuitry. 
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